- Home
- TOPS vs PASG Comparison
TOPS vs PASG Comparison
Compare TOPS & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- PASG
- Stock Information
- Founded
- TOPS 2000
- PASG 2017
- Country
- TOPS Greece
- PASG United States
- Employees
- TOPS N/A
- PASG N/A
- Industry
- TOPS Marine Transportation
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- PASG Health Care
- Exchange
- TOPS Nasdaq
- PASG Nasdaq
- Market Cap
- TOPS 27.0M
- PASG 27.6M
- IPO Year
- TOPS 2004
- PASG 2020
- Fundamental
- Price
- TOPS $5.91
- PASG $7.43
- Analyst Decision
- TOPS
- PASG Strong Buy
- Analyst Count
- TOPS 0
- PASG 4
- Target Price
- TOPS N/A
- PASG $59.25
- AVG Volume (30 Days)
- TOPS 8.9K
- PASG 38.3K
- Earning Date
- TOPS 11-14-2025
- PASG 11-10-2025
- Dividend Yield
- TOPS N/A
- PASG N/A
- EPS Growth
- TOPS N/A
- PASG N/A
- EPS
- TOPS 2.30
- PASG N/A
- Revenue
- TOPS $87,872,000.00
- PASG N/A
- Revenue This Year
- TOPS $9.90
- PASG N/A
- Revenue Next Year
- TOPS N/A
- PASG N/A
- P/E Ratio
- TOPS $2.66
- PASG N/A
- Revenue Growth
- TOPS 4.77
- PASG N/A
- 52 Week Low
- TOPS $5.00
- PASG $5.12
- 52 Week High
- TOPS $11.47
- PASG $26.60
- Technical
- Relative Strength Index (RSI)
- TOPS 58.38
- PASG 44.51
- Support Level
- TOPS $5.92
- PASG $6.82
- Resistance Level
- TOPS $6.21
- PASG $7.90
- Average True Range (ATR)
- TOPS 0.29
- PASG 0.68
- MACD
- TOPS 0.02
- PASG -0.16
- Stochastic Oscillator
- TOPS 82.84
- PASG 28.11
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.